Hendrik Reynaert

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 438 citations

Fibrosis, Hepatology, Liver Physiology +9

A Biodegradable Esophageal Stent in the Treatment of a Corrosive Esophageal Stenosis in a Child

Yvan Vandenplas, Bruno Hauser, Thierry Devreker et al. · Journal of Pediatric Gastroenterology and Nutrition · 2009 · 369 citations

The Hippo pathway effector YAP controls mouse hepatic stellate cell activation

Inge Mannaerts, Sofia Batista Leite, Stefaan Verhulst et al. · Journal of Hepatology · 2015 · 368 citations

Developmental Biology, Signal Transduction, Molecular Physiology +6

Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With -308 TNF Gene Polymorphism

Édouard Louis, Séverine Vermeire, P. Rutgeerts et al. · Scandinavian Journal of Gastroenterology · 2002 · 242 citations · Full text

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

Séverine Vermeire, Édouard Louis, An Carbonez et al. · The American Journal of Gastroenterology · 2002 · 224 citations · Full text